Loading...

Andy Tompkins, MD, MHS

Title(s)Associate Professor, Psychiatry
SchoolSchool of Medicine
Phone415-206-3645
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Emory University, Atlanta, GABS05/1999Biology / English
    New York Medical College, Valhalla, NYMD05/2004Medicine
    Johns Hopkins Bayview Medical Center, Baltimore, MDInternship06/2005Psychiatry-Medicine
    Johns Hopkins Hospital, Baltimore, MDResidency06/2008Psychiatry
    Johns Hopkins University School of Medicine, Baltimore, MDPost-doctoral Fellowship06/2010Behavioral Pharmacology / Addictions
    Johns Hopkins Bloomberg School of Public Health, Baltimore, MDMHS08/2014Clinical Investigation

    Collapse Research 
    Collapse Research Activities and Funding
    Project HOUDINI LINK: Hospital Opioid Use Disorder treatment Initiation and LINKage to care
    SAMHSA H79TI081419-01Sep 30, 2018 - Sep 29, 2021
    Role: Executive Director / PI
    Improving the Opioid Treatment Outpatient Program (OTOP) through the Addition of Yoga Therapy
    San Francisco General Hospital Foundation 34843Jul 1, 2018 - Jun 30, 2019
    Role: Principal Investigator
    Opioid and cannabinoid combinations in laboratory and clinical pain
    NIH R01DA042751May 15, 2017 - Apr 30, 2020
    Role: Co-Investigator
    Using Cannabinoids to Enhance Opioid Analgesic Effects in Humans
    NIH R01DA040644Aug 1, 2016 - Jun 30, 2021
    Role: Co-Investigator
    Role of Sleep in the Treatment of Cannabis Dependence
    NIH U01DA031784Jul 1, 2012 - Jun 30, 2017
    Role: Co-Investigator
    Optimizing Pain Treatment while Reducing Abuse Liability in Opioid Dependence
    NIH K23DA029609Jul 1, 2012 - May 31, 2017
    Role: Principal Investigator
    Mechanisms of Sleep Disruption Hyperalgesia
    NIH/NIDA R01DA032922Jun 1, 2012 - Aug 31, 2017
    Role: Co-Investigator
    Multisite Controlled Trial of Cocaine Vaccine (3 of 6) Baltimore Treatment Site
    NIH R01DA025251Sep 15, 2008 - Jan 31, 2013
    Role: Co-Investigator
    Clinical Trial of Topiramate for Cocaine Addiction
    NIH R01DA021808Sep 20, 2006 - Jul 31, 2012
    Role: Co-Investigator
    Human Behavioral Pharmacology of Substance Abuse
    NIH 2T32DA007209-26Feb 1, 1981 - Jun 30, 2011
    Role: Post-doctoral Fellow
    Human Behavioral Pharmacology of Substance Abuse
    NIH 5T32DA007209-27Feb 1, 1981 - Jun 30, 2011
    Role: Post-doctoral Fellow

    Collapse ORNG Applications 
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hay KR, Huhn AS, Tompkins DA, Dunn KE. Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use. J Addict Med. 2019 Jan 04. PMID: 30633045.
      View in: PubMed
    2. Dunn KE, Weerts EM, Huhn AS, Schroeder JR, Tompkins DA, Bigelow GE, Strain EC. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. Addict Biol. 2018 Oct 08. PMID: 30295400.
      View in: PubMed
    3. Satre DD, Borsari B, Tompkins DA, Ramo D. Psychiatric Disorders and Comorbid Cannabis Use: When Should We Be Concerned and What Can We Do About It? J Clin Psychiatry. 2018 Sep 11; 79(6). PMID: 30256546.
      View in: PubMed
    4. Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Drug Alcohol Depend. 2018 06 01; 187:171-178. PMID: 29674251.
      View in: PubMed
    5. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018 Jul; 113(7):1188-1209. PMID: 29396985.
      View in: PubMed
    6. Dunn KE, Tompkins DA, Strain EC. Tramadol Extended-Release and Opioid Withdrawal Management-Legal Implications-Reply. JAMA Psychiatry. 2018 Feb 01; 75(2):215. PMID: 29282473.
      View in: PubMed
    7. Huhn AS, Tompkins DA, Dunn KE. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug Alcohol Depend. 2017 11 01; 180:279-285. PMID: 28942031.
      View in: PubMed
    8. Dunn KE, Tompkins DA, Bigelow GE, Strain EC. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Sep 01; 74(9):885-893. PMID: 28700791.
      View in: PubMed
    9. Tompkins DA, Huhn AS, Johnson PS, Smith MT, Strain EC, Edwards RR, Johnson MW. To take or not to take: the association between perceived addiction risk, expected analgesic response and likelihood of trying novel pain relievers in self-identified chronic pain patients. Addiction. 2018 Jan; 113(1):67-79. PMID: 28645137.
      View in: PubMed
    10. Tompkins DA, Hobelmann JG, Compton P. Providing chronic pain management in the "Fifth Vital Sign" Era: Historical and treatment perspectives on a modern-day medical dilemma. Drug Alcohol Depend. 2017 04 01; 173 Suppl 1:S11-S21. PMID: 28363315.
      View in: PubMed
    11. Tompkins DA, Johnson PS, Smith MT, Strain EC, Edwards RR, Johnson MW. Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes. Pain. 2016 08; 157(8):1724-32. PMID: 27075431.
      View in: PubMed
    12. Drescher J, Schwartz A, Casoy F, McIntosh CA, Hurley B, Ashley K, Barber M, Goldenberg D, Herbert SE, Lothwell LE, Mattson MR, McAfee SG, Pula J, Rosario V, Tompkins DA. The Growing Regulation of Conversion Therapy. J Med Regul. 2016; 102(2):7-12. PMID: 27754500.
      View in: PubMed
    13. Tompkins DA, Sides JA, Harrison JA, Strain EC. Recruitment techniques for alcohol pharmacotherapy clinical trials: A cost-benefit analysis. Addict Disord Their Treat. 2015 Dec; 14(4):211-219. PMID: 26752979.
      View in: PubMed
    14. Dunn KE, Finan PH, Tompkins DA, Fingerhood M, Strain EC. Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. Drug Alcohol Depend. 2015 Dec 01; 157:143-9. PMID: 26518253; PMCID: PMC4663104 [Available on 12/01/16].
      View in: PubMed, PubMed Central
    15. Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol. 2014 Oct; 135(1):163-71. PMID: 25072931; PMCID: PMC4404750.
      View in: PubMed, PubMed Central
    16. Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, Strain EC, Bigelow GE. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend. 2014 Jul 01; 140:92-100. PMID: 24814607; PMCID: PMC4431633.
      View in: PubMed, PubMed Central
    17. Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, Kampman K. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 2014 Jul 01; 140:42-7. PMID: 24793366; PMCID: PMC4073297.
      View in: PubMed, PubMed Central
    18. Tompkins DA, Smith MT, Bigelow GE, Moaddel R, Venkata SL, Strain EC. The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males. Clin J Pain. 2014 Jan; 30(1):36-45. PMID: 23446076; PMCID: PMC3676462.
      View in: PubMed, PubMed Central
    19. Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther. 2014 Feb; 348(2):217-26. PMID: 24227768; PMCID: PMC3912547.
      View in: PubMed, PubMed Central
    20. Antoine DG, Strain EC, Tompkins DA, Bigelow GE. Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):369-72. PMID: 23369645; PMCID: PMC3911782.
      View in: PubMed, PubMed Central
    21. Byne W, Bradley SJ, Coleman E, Eyler AE, Green R, Menvielle EJ, Meyer-Bahlburg HF, Pleak RR, Tompkins DA. Report of the American Psychiatric Association Task Force on Treatment of Gender Identity Disorder. Arch Sex Behav. 2012 Aug; 41(4):759-96. PMID: 22736225.
      View in: PubMed
    22. Byne W, Bradley SJ, Coleman E, Eyler AE, Green R, Menvielle E, Meyer-Bahlburg HF, Pleak RR, Tompkins DA. Treatment of gender identity disorder. Am J Psychiatry. 2012 Aug; 169(8):875-6. PMID: 22854940.
      View in: PubMed
    23. Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep. 2011 Apr; 15(2):129-36. PMID: 21225380; PMCID: PMC3165032.
      View in: PubMed, PubMed Central
    24. Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology (Berl). 2010 Jul; 210(4):471-80. PMID: 20386884; PMCID: PMC2878387.
      View in: PubMed, PubMed Central
    25. Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009 Nov 01; 105(1-2):154-9. PMID: 19647958; PMCID: PMC2774236.
      View in: PubMed, PubMed Central
    26. Gerbino-Rosen G, Roofeh D, Tompkins DA, Feryo D, Nusser L, Kranzler H, Napolitano B, Frederickson A, Henderson I, Rhinewine J, Kumra S. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005 Oct; 44(10):1024-31. PMID: 16175107.
      View in: PubMed
    27. Wei Y, Chen J, Rosas G, Tompkins DA, Holt PA, Rao R. Phenotypic screening of mutations in Pmr1, the yeast secretory pathway Ca2+/Mn2+-ATPase, reveals residues critical for ion selectivity and transport. J Biol Chem. 2000 Aug 04; 275(31):23927-32. PMID: 10801855.
      View in: PubMed
    Andy's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (140) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (3) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑